Expert Review of Neurotherapeutics最新文献_第2页

Preferences, tailoring, and self-tailoring in internet-delivered treatments: lessons learned. 互联网治疗中的偏好、定制和自定制：经验教训。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-05-01 Epub Date: 2026-03-30 DOI: 10.1080/14737175.2026.2652294

Gerhard Andersson, Per Carlbring

{"title":"Preferences, tailoring, and self-tailoring in internet-delivered treatments: lessons learned.","authors":"Gerhard Andersson, Per Carlbring","doi":"10.1080/14737175.2026.2652294","DOIUrl":"10.1080/14737175.2026.2652294","url":null,"abstract":"Introduction: Internet-delivered psychological treatments have been developed and tested in many trials and are also implemented.Areas covered: The authors focus on treatment preferences when clients are allowed to choose treatment orientation and how the treatment is set up. The literature was searched using Medline, Google Scholar and Scopus in November 2025, locating eight preference studies. They showed benefits in treatment satisfaction when preferences are included and possibly improved outcomes. The second focus was on tailored internet-delivered cognitive behavior therapy (ICBT). The authors review six recent controlled studies published from 2000 onwards on various subjects including COVID-19, domestic violence, chronic pain, climate distress, depression in older adults in Lithuania, and young adults with anxiety and depression in Brazil. These examples are in line with previous findings showing that tailored ICBT is effective, despite there being no clear benefits over diagnosis-specific or transdiagnostic ICBT. Finally, the authors reviewed published findings from two trials demonstrating that self-tailoring can work without clinician input.Expert opinion: There are robust findings showing that tailored internet interventions are effective, with further indication that preferences and self-tailoring may work too. Future research will likely incorporate artificial intelligence tools to a greater extent to improve treatment efficacy.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"477-483"},"PeriodicalIF":3.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147572560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gene therapy for Parkinson's disease: current landscape, translational challenges, and future directions. 帕金森病的基因治疗：现状、转化挑战和未来方向。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-05-01 Epub Date: 2026-04-02 DOI: 10.1080/14737175.2026.2647033

Vito Evola, Mayur S Parmar

{"title":"Gene therapy for Parkinson's disease: current landscape, translational challenges, and future directions.","authors":"Vito Evola, Mayur S Parmar","doi":"10.1080/14737175.2026.2647033","DOIUrl":"10.1080/14737175.2026.2647033","url":null,"abstract":"Introduction: Parkinson's disease (PD) is a progressive neurodegenerative disorder marked by dopaminergic neuronal loss. Gene therapy has emerged as a disease-modifying strategy capable of targeting these mechanisms through dopamine restoration, neurotrophic support, and correction or silencing of pathogenic mutations, which collectively contribute to neuronal vulnerability and α-Synuclein-driven degeneration.Areas covered: Herein, the authors synthesize contemporary viral and non‑viral platforms designed to restore dopamine biosynthesis, deliver neurotrophic factors, and correct pathogenic mutations (GBA1, LRRK2, PINK1). The authors summarize clinical translation with emphasis on trials targeting dopamine synthesis (AAV2 AADC, ProSavin/AXO Lenti PD), neurotrophic factors (AAV2 GDNF, AAV2 NRTN), pathogenic variants (AAV9 GBA1/PR001; LRRK2 RNAi; emerging CRISPR/PINK1 strategies), and circuit modulation (AAV GAD), correlating mechanistic ration. They also examine translational challenges including vector biodistribution and immune responses.Expert opinion: Gene therapy for PD is transitioning from symptomatic modulation toward targeted molecular correction. Clinical trials have validated durable, neuron-specific expression using AAV and lentiviral vectors and demonstrated target engagement across dopamine synthesis, trophic support, and genetic mutation-specific strategies. Persistent challenges include limited vector biodistribution, reduced retrograde transport in advanced disease, immune variability, and surgical infrastructure requirements. Overcoming these via engineered capsids, delivery optimization, and validated biomarkers will enable precision, stage‑specific interventions.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"425-442"},"PeriodicalIF":3.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147467429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A critical review of midazolam 10 mg autoinjector for the treatment of convulsive status epilepticus in adults. 咪达唑仑10mg自动注射器治疗成人惊厥性癫痫持续状态的综述。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-05-01 Epub Date: 2026-03-28 DOI: 10.1080/14737175.2026.2652300

Francesco Brigo, Simona Lattanzi

{"title":"A critical review of midazolam 10 mg autoinjector for the treatment of convulsive status epilepticus in adults.","authors":"Francesco Brigo, Simona Lattanzi","doi":"10.1080/14737175.2026.2652300","DOIUrl":"10.1080/14737175.2026.2652300","url":null,"abstract":"Introduction: Status epilepticus is a neurological emergency in which rapid treatment is essential to reduce morbidity and mortality. Delays in establishing intravenous access frequently hinder timely benzodiazepine administration, creating a critical need for fast, reliable, and user-friendly non-IV rescue therapies. The midazolam 10 mg autoinjector was developed to address these operational barriers and improve prehospital seizure management.Areas covered: This review examines the pharmacology, clinical efficacy, safety, and regulatory status of the midazolam autoinjector, drawing on published studies of intramuscular midazolam, pharmacokinetic evaluations of autoinjector formulations, and regulatory documents supporting its approval.Expert opinion: The midazolam autoinjector offers a meaningful advance in the treatment of status epilepticus by enabling rapid, consistent intramuscular delivery without preparation. Its design directly addresses the practical limitations of existing therapies and is likely to encourage adoption in prehospital and other time-critical settings. As emergency care increasingly prioritizes early intervention, autoinjector-based benzodiazepines are poised to play an expanding role in modern seizure-rescue strategies.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"419-424"},"PeriodicalIF":3.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147528065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cognitive and motivational therapy for problematic alcohol use and alcohol use disorder in older adults: a systematic review. 认知和动机疗法对老年人酒精使用问题和酒精使用障碍的治疗：一项系统综述

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-04-30 DOI: 10.1080/14737175.2026.2665653

Jennifer J Park, Kangxin Zhang, Goeun Lee, Marcus Lee, Anika Mohapatra, Marc N Potenza

{"title":"Cognitive and motivational therapy for problematic alcohol use and alcohol use disorder in older adults: a systematic review.","authors":"Jennifer J Park, Kangxin Zhang, Goeun Lee, Marcus Lee, Anika Mohapatra, Marc N Potenza","doi":"10.1080/14737175.2026.2665653","DOIUrl":"https://doi.org/10.1080/14737175.2026.2665653","url":null,"abstract":"Introduction: Cognitive and motivational therapies for alcohol use disorder (AUD) and problematic alcohol use have demonstrated effectiveness in youth and general adults, yet evidence specific to older adults has not been synthesized. This systematic review summarizes cognitive and motivational interventions in older adults.Methods: PubMed, PsycINFO, Embase, and Web of Science were searched. Eligible studies included participants aged ≥55 years with AUD or problematic alcohol use and evaluated cognitive or motivational therapies. Studies without alcohol-related outcomes were excluded. The Effective Public Health Practice Project Quality Assessment Tool was used.Results: Seven studies involving 1121 participants were identified. Motivational approaches were most common (4/7 studies; 813 participants, 72.5%), whereas combined cognitive-motivational approaches (1/7 studies; 158 participants, 14.1%), CBT-like approaches (1/7 studies; 60 participants, 5.4%), and other non-motivational cognitive interventions (1/7 studies; 90 participants, 8.0%) were represented by single studies. Treatments generally improved alcohol-consumption-related outcomes, although comparative efficacy was less clear. Although cognitive and motivational therapy for AUD and problematic alcohol use in older adults appear promising, definitive conclusions cannot be drawn as evidence is limited by methodological concerns including limited and heterogeneous evidence from randomized controlled trials, small sample sizes, limited long-term follow-up, and insufficient reporting of intervention components.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-12"},"PeriodicalIF":3.4,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147766760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Game changer: direct observation to improve personalized psychotherapy in adolescent gaming disorder. 游戏改变者：直接观察改善青少年游戏障碍的个性化心理治疗。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-04-29 DOI: 10.1080/14737175.2026.2661664

Lucien Rochat, Sofia Arango Arroyave, Sophia Achab

引用次数: 0

When and in what patient segments are low-intensity and remote interventions valuable for treating symptoms of post-concussion syndrome. 低强度和远程干预对治疗脑震荡后综合征的症状有价值的时间和对象。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-04-29 DOI: 10.1080/14737175.2026.2665651

María Julieta Russo, Fernando Salvat

引用次数: 0

Exploring the differential diagnosis of generalized diabetic peripheral neuropathy. 探讨糖尿病周围神经病变的鉴别诊断。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-04-27 DOI: 10.1080/14737175.2026.2665649

Jenyfer Fuentes Mendoza, Marcio José Concepción Zavaleta, Alejandro Lopez Ramos, Camila Mondragón Portal, Luisa Graciela Dongo Dueñas, Jeny Justina Mendoza Godoy, Luis Concepción-Urteaga, José Paz-Ibarra

{"title":"Exploring the differential diagnosis of generalized diabetic peripheral neuropathy.","authors":"Jenyfer Fuentes Mendoza, Marcio José Concepción Zavaleta, Alejandro Lopez Ramos, Camila Mondragón Portal, Luisa Graciela Dongo Dueñas, Jeny Justina Mendoza Godoy, Luis Concepción-Urteaga, José Paz-Ibarra","doi":"10.1080/14737175.2026.2665649","DOIUrl":"https://doi.org/10.1080/14737175.2026.2665649","url":null,"abstract":"Introduction: Diabetic peripheral neuropathy (DPN) is the most common chronic complication of diabetes mellitus and is frequently assumed to be the sole cause of neuropathic symptoms in patients with diabetes. This diagnostic simplification may lead to misdiagnosis, delayed treatment of alternative etiologies, and preventable neurological disability. Accurate differentiation between DPN and non-diabetic neuropathies remains a major clinical challenge.Areas covered: This narrative review examines the principal differential diagnoses of generalized DPN, integrating clinical presentation, disease tempo, electrophysiological patterns, and targeted laboratory evaluation. A structured literature search of PubMed, Scopus, and Web of Science (2015 2025) was conducted, focusing on inflammatory, nutritional, toxic, hereditary, amyloid, autoimmune, and systemic causes of peripheral neuropathy. Emerging diagnostic tools, including biomarkers and advanced neurophysiological techniques, are also discussed, and a practical diagnostic algorithm is proposed to support real-world clinical decision-making.Expert opinion: DPN should be regarded as a diagnosis of exclusion rather than a default explanation in patients with diabetes. A phenotype-driven and structured diagnostic approach is essential to reduce diagnostic anchoring, prevent iatrogenic harm, and enable early identification of treatable neuropathies, ultimately improving neurological outcomes and precision medicine strategies.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-15"},"PeriodicalIF":3.4,"publicationDate":"2026-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147766837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current and emerging therapeutic advancements for Niemann-Pick disease type C: where are we now and what does the future hold? C型尼曼-匹克病目前和正在出现的治疗进展：我们现在在哪里，未来会怎样？

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-04-20 DOI: 10.1080/14737175.2026.2661657

Andreas Hahn

{"title":"Current and emerging therapeutic advancements for Niemann-Pick disease type C: where are we now and what does the future hold?","authors":"Andreas Hahn","doi":"10.1080/14737175.2026.2661657","DOIUrl":"https://doi.org/10.1080/14737175.2026.2661657","url":null,"abstract":"Introduction: Niemann-Pick Disease Type C (NPD Type C) is a rare lysosomal disease characterized by progressive neurovisceral manifestations due to abnormal lipid storage resulting from biallelic mutations in the NPC1 or NPC2 gene. Until recently, treatment was mainly symptomatic.Areas covered: This review summarizes the results of newer clinical trials evaluating efficacy and safety of new therapeutics, e.g. miglustat, cyclodextrins, arimoclomol, and N-Acetyl-L Leucine (NALL) for the treatment of NPD Type C. The PubMed database and the clinicaltrials.gov website were used for literature search and newest results posted.Expert opinion: Arimoclomol and NALL showed significant improvements of neurological symptoms and reasonable safety profiles in phase II/III trials. The recent approval of arimoclomol in combination with miglustat and NALL for patients with NPD type C has the potential to modify the standard of care and will hopefully improve the prognosis. However, the collection of real-world data is warranted to explore the real clinical value of these new medicaments. Cyclodextrins are also promising therapeutics that principally allow to correct basic pathophysiological mechanisms in NPD type C, but further research is needed.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-7"},"PeriodicalIF":3.4,"publicationDate":"2026-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147728712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The value and risks of antidepressant therapy in Alzheimer's disease: a field update and its clinical implications. 抗抑郁药治疗阿尔茨海默病的价值和风险：领域更新及其临床意义

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-04-06 DOI: 10.1080/14737175.2026.2653170

Polona Rus Prelog, Blanka Kores Plesničar, Matija Zupan, Senta Frol, Milica Gregorič Kramberger

{"title":"The value and risks of antidepressant therapy in Alzheimer's disease: a field update and its clinical implications.","authors":"Polona Rus Prelog, Blanka Kores Plesničar, Matija Zupan, Senta Frol, Milica Gregorič Kramberger","doi":"10.1080/14737175.2026.2653170","DOIUrl":"https://doi.org/10.1080/14737175.2026.2653170","url":null,"abstract":"Introduction: Depression is one of the most frequent and disabling neuropsychiatric syndromes in Alzheimer's disease (AD), yet antidepressant use is still largely extrapolated from late‑life depression and is poorly aligned with emerging evidence on 'neurodegenerative depression' and disease‑modifying therapies. This article critically re‑examines the clinical value and risks of antidepressants in AD.Areas covered: Drawing on a narrative search of PubMed/MEDLINE and Embase (January 2000-December 2025) and targeted review of recent guidelines and anti‑amyloid trials, the article synthesizes randomized and observational data on efficacy and safety across antidepressant classes, highlighting modest and inconsistent benefits alongside adverse outcomes such as falls, hyponatremia, bleeding, mortality and possible acceleration of cognitive decline. It integrates mechanistic work on synaptic loss, neuroinflammation and network disruption, discusses the exclusion of depressed patients from anti‑amyloid trials, and reviews rapid‑acting, neuromodulatory and psychosocial strategies within a proposed precision‑prescribing framework based on biomarkers, vascular burden and symptom dimensions.Expert opinion: Monoaminergic antidepressants in AD should not be abandoned but repositioned as time‑limited, closely monitored options for clearly defined, functionally impairing depressive syndromes, embedded in multimodal care rather than used as default, long‑term treatment for non‑specific distress. Future priorities include biomarker‑stratified AD depression trials, evaluation of interactions with anti‑amyloid therapies and rigorous testing of non‑monoaminergic interventions.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-15"},"PeriodicalIF":3.4,"publicationDate":"2026-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147622099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The postpartum period and bipolar disorder: early identification, prevention, and management. 产后与双相情感障碍：早期识别、预防和管理。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-04-01 DOI: 10.1080/14737175.2026.2653163

Verinder Sharma

{"title":"The postpartum period and bipolar disorder: early identification, prevention, and management.","authors":"Verinder Sharma","doi":"10.1080/14737175.2026.2653163","DOIUrl":"https://doi.org/10.1080/14737175.2026.2653163","url":null,"abstract":"Introduction: New-onset or worsening bipolar disorder is common after childbirth and is associated with increased risk of psychiatric hospitalization, along with safety concerns for the mother and newborn. Despite the availability of several medications, preventing postpartum bipolar mood episodes remains difficult.Areas covered: This narrative review outlines findings of a search of MEDLINE/PubMed, PsycINFO, and the Cochrane Database of Systematic Reviews in November 2025. The author examines the challenges of preventing postpartum mood episodes in women with bipolar disorder and discusses opportunities for early detection and treatment of symptoms during and after pregnancy. Continuation of optimized maintenance treatment to mitigate the risk of recurrence associated with weaning and resumption of menstruation is emphasized. This review also highlights research gaps, particularly the lack of treatment studies.Expert opinion: Efforts to prevent postpartum episodes of bipolar disorder should include timely identification of at-risk individuals, confirming diagnosis and psychiatric comorbidities, reviewing illness course, and analyzing risk and protective factors, psychoeducation, mitigating risk factors, vigilant monitoring for emerging symptoms of relapse or recurrence, tailoring treatment, assessing breastfeeding safety and compatibility, and addressing safety concerns. Follow-up should continue for several months, as mothers remain at risk of relapse during weaning, resumption of menstruation, and the return to work after maternity leave.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-13"},"PeriodicalIF":3.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147591080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0